A novel synthesised STAT3 inhibitor exerts potent anti-tumour activity by inducing lysosome-dependent cell death

• Published in: British journal of pharmacology Vol. 182; no. 17; p. 4041
• Main Authors: Xu, Marvin Xuejun, Liu, Xinxin, Zhang, Hai-Liang, Xu, Hongyun, Ma, Xiangyu, Yang, Yupo, Duan, Chaoqun, Tang, Shanshun, Liu, Yaqing, Li, Cen, Pei, Mengfu, Xia, Junkai, Yang, Yali, Guo, Yanmin, Wang, Yang, Luo, Songping, Ma, Jianguo, Yang, Zhengyan, Zhu, Xiao-Feng, Xu, Chun-Ping
• Format: Journal Article
• Language: English
• Published: England 01.09.2025
• Subjects: Animals; Antineoplastic Agents - chemical synthesis; Cell Death - drug effects; Cell Line, Tumor; Female; Humans; Lysosomes - drug effects; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Docking Simulation; Random Allocation; STAT3 Transcription Factor - antagonists & inhibitors; Xenograft Model Antitumor Assays; RDp002; triple‐negative breast cancer (TNBC); STAT3 inhibitor; multiple myeloma (MM); lysosome‐dependent cell death

Signal transducer and activator of transcription 3 (STAT3) has emerged as a promising therapeutic target for triple-negative breast cancer (TNBC) and multiple myeloma (MM), yet no STAT3-selective drugs have been approved for clinical use. Newly synthesized compounds were screened by docking, surface...